A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
暂无分享,去创建一个
D. Katzenstein | K. Marder | K. Tashima | D. Clifford | T. Flynn | R. Ellis | C. Marra | C. Marra | D. Kolson | G. Schifitto | D. Simpson | E. Miller | E. Singer | V. Valcour | B. Cohen | N. Sacktor | S. Evans | L. Millar | M. Watters | Jingwu Z. Zhang | D. Mildvan | R. Remmel | V. Hung | N. Venna | Kerryn D. Carter | N. Hanks | S. Chafey | E. Smith | Joseph Quinn | M. Shoemaker | Shelia B Dunaway | J. Bailey | D. Currin | R. Remmel | K. Nuffer | D. Burgess | H. Sousa | J. Zhang | J. Weihe | Mary S. Gould | S. Cahill | M. Perrin | T. Spitz | R. Clouse | Ramon Diaz‐Arrastia | A. Weisbeck | L. Reisberg | C. Lohner | S. Pedersen | Linda Millar
[1] W. Cass,et al. Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum , 2006, Experimental Neurology.
[2] H. Gendelman,et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report , 2006, Neurology.
[3] C. Power,et al. Regulation of neural cell survival by HIV-1 infection , 2006, Neurobiology of Disease.
[4] J. Corbeil,et al. Methamphetamine stimulates interferon inducible genes in HIV infected brain , 2005, Journal of Neuroimmunology.
[5] I. Grant,et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine , 2005, Neurology.
[6] R. Cutler,et al. Novel markers of oxidative stress in actively progressive HIV dementia , 2004, Journal of Neuroimmunology.
[7] K. Marder,et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. , 2004, Archives of neurology.
[8] Robert K. Heaton,et al. Predictive Validity of Global Deficit Scores in Detecting Neuropsychological Impairment in HIV Infection , 2004, Journal of clinical and experimental neuropsychology.
[9] M. Mattson,et al. Perturbation of sphingolipid metabolism and ceramide production in HIV‐dementia , 2004, Annals of neurology.
[10] A. Nath,et al. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat , 2003, Brain Research.
[11] S. Fujimoto,et al. Subject Index Vol. 59, 2003 , 2003, Hormone Research in Paediatrics.
[12] K. Marder,et al. Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment , 2003, Neurology.
[13] D. Butterfield,et al. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants , 2003, Neurology.
[14] K. Marder,et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive–motor impairment , 2002, Neurology.
[15] A. Nath,et al. Human immunodeficiency virus‐1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function , 2002, Journal of neurochemistry.
[16] D. Butterfield,et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death , 2002, Neurobiology of Aging.
[17] D. Butterfield,et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. , 2001, Trends in molecular medicine.
[18] K. Marder,et al. Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study , 2000, Neurology.
[19] S. Lipton,et al. A phase I/II trial of nimodipine for HIV-related neurologic complications , 1998, Neurology.
[20] N. Sacktor. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment , 1998, Neurology.
[21] M. Beal,et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.
[22] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[23] W. Tatton. Modulation of gene expression rather than monoamine oxidase inhibition , 1996, Neurology.
[24] L. Wilkins. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder , 1996, Neurology.
[25] J. Becker,et al. Cognitive performance after progression to AIDS , 1995, Neurology.
[26] J. Coyle,et al. Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.
[27] P. Yu,et al. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[28] M. Hirsch,et al. Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial , 1993, Annals of neurology.
[29] P. Salo,et al. Deprenyl reduces the death of motoneurons caused by axotomy , 1992, Journal of neuroscience research.
[30] W. Tatton,et al. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism , 1991, Journal of neuroscience research.
[31] E. Miller,et al. Computerized and conventional neuropsychological assessment of HIV‐1‐infected homosexual men , 1991, Neurology.
[32] O. Selnes,et al. Normative Data for a Brief Neuropsychological Screening Battery , 1991, Perceptual and motor skills.
[33] Y. Kumagae,et al. Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia , 1991, Neuroscience Letters.
[34] J. Becker,et al. Neuropsychological performance in HIV‐1‐infected homosexual men , 1990, Neurology.
[35] N. Larocca,et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.
[36] L. Radloff. The CES-D Scale , 1977 .
[37] H. Werner,et al. Interference effects of Stroop color-word test in childhood, adulthood, and aging. , 1962, The Journal of genetic psychology.
[38] R. Reitan. Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .
[39] M. Beal,et al. Bioenergetic approaches for neuroprotection in Parkinson's disease , 2003, Annals of neurology.
[40] L. Schneider,et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. , 1998, Archives of neurology.
[41] M. Carrillo,et al. (-)deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. , 1994, Life sciences.
[42] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.
[43] L. Bérubé,et al. [Clinical neuropsychology]. , 1982, Nursing Quebec.
[44] A. Rey. L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). , 1941 .